The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.
Bas W.G. van Rhijn(Meertens Institute), Ellen C. Zwarthoff(Erasmus MC), Irene Lurkin(Erasmus University Rotterdam), Theodorus van der Kwast(Erasmus MC), François Radvanyi(Centre National de la Recherche Scientifique), Wim J. Kirkels(Erasmus MC)
PubMed
February 15, 2001
Cited by 309
Related Papers
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
|The Lancet Oncology|2010|944
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654